Drug Trial Radar · NCT07704645
The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Aug 2026
Primary completion
Jun 2028
Study completion Dec 2029
Sponsor
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, multicenter phase II clinical trial of adebelizumab combined with other anti-tumor therapies in patients with non-small cell lung cancer. The aim of this study was to evaluate the safety, tolerability and efficacy of adebelizumab combined with other anti-tumor therapies in patients with resectable non-small cell lung cancer ( NSCLC )
Conditions
- Resectable Non-small Cell Lung Cancer
Interventions
Adebrelimab Injection combined with SHR-1826 Injection combined with SHR-8068 InjectionDrug
Adebrelimab Injection combined with SHR-1826 Injection combined with SHR-8068 Injection
Adebrelimab Injection combined with HRS-7058 CapsuleDrug
Adebrelimab Injection combined with HRS-7058 Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathological complete response (pCR) rate: pCR is defined as the absence of any residual tumor at the time of surgical resection.Time frame: All results are expected to be obtained in the last participant three months after surgery.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.